Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12675116 | 0.89 | ALDH1A1 (0.39) | KMT2AALDH1A1MEN1MAPTMDM2 | |
| SCHEMBL2599925 | 0.87 | TAS2R14 (0.36) | KMT2AMEN1RAB9ANR1H4 | |
| SCHEMBL12640378 | 0.86 | PPARD (0.39) | NR1H4 | |
| SCHEMBL12674823 | 0.84 | ALDH1A1 (0.41) | KMT2AALDH1A1MEN1MAPTMDM2 | |
| SCHEMBL12640354 | 0.82 | ALDH1A1 (0.42) | KMT2AALDH1A1MEN1MAPTMDM2 | |
| SCHEMBL12640371 | 0.80 | ADORA2B (0.33) | — | |
| SCHEMBL12640369 | 0.79 | PIK3CA (0.35) | — | |
| SCHEMBL12675297 | 0.78 | ALDH1A1 (0.37) | KMT2AALDH1A1MEN1MAPTMDM2 | |
| SCHEMBL12674774 | 0.77 | ALDH1A1 (0.42) | KMT2AALDH1A1MEN1MAPTMDM2 | |
| SCHEMBL12640364 | 0.77 | SLC13A5 (0.37) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2011057022-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110112127-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112127-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | KMT2A 1521/4885ALDH1A1 2981/4885MEN1 301/4885 |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | KMT2A 1521/4885ALDH1A1 2981/4885MEN1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.